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Abstract
Background: During last years, there has been an intensive search for blood 
biomarkers in schizophrenia to assist in diagnosis, prognosis and clinical management 
of the disease. Methods: In this study, we first conducted a weighted gene 
coexpression network analysis to address differentially expressed genes in peripheral 
blood from patients with chronic schizophrenia (n = 30) and healthy controls (n = 15). 
The discriminating performance of the candidate genes was further tested in an 
independent cohort of patients with first-episode schizophrenia (n = 124) and healthy 
controls (n = 54), and in postmortem brain samples (cingulate and prefrontal cortices) 
from patients with schizophrenia (n = 34) and healthy controls (n = 35). Results: The 
expression of the Eukaryotic Translation Initiation Factor 2D (EIF2D) gene, which is 
involved in protein synthesis regulation, was increased in the chronic patients of 
schizophrenia. On the contrary, the expression of the Thymocyte Selection-Associated 
High Mobility Group Box (TOX) gene, involved in immune function, was reduced. EIF2D 
expression was also altered in first-episode schizophrenia patients, but showing 
reduced levels.  Any of the postmortem brain areas studied did not show differences of 
expression of both genes. Conclusions: EIF2D and TOX are putative blood markers of 
chronic patients of schizophrenia, which expression change from the onset to the 
chronic disease, unraveling new biological pathways that can be used for the 
development of new intervention strategies in the diagnosis and prognosis of 
schizophrenia disease.  
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1. Introduction
During recent decades, great efforts have been made to understand the molecular 
basis of schizophrenia (SZ). As a result, a growing list of genetic polymorphisms, rare 
genetic variants, de novo mutations, epigenetic changes and other genomic alterations 
showing association with SZ has been provided(1-3). However, these findings have not 
been translated into suitable biomarkers for clinical use because most markers account 
for low disease risk and those based on gene expression in postmortem brain tissues 
cannot be analyzed since brain biopsies are not acceptable for clinical evaluation.
Blood is a good source of samples for disease assessment in living patients because 
this tissue is easily accessible and is in contact with tissues and cells throughout the 
body. Many studies have showed that alteration of metabolism and cellular functions 
in the central nervous system (CNS), as well as disturbances in neurotransmitter and 
hormonal systems are related with altered function and metabolism of blood cells (4, 
5). This connection results from a complex network involving the nervous, endocrine 
and immune systems and has been investigated in several neuropsychiatric disorders. 
Different studies have compared gene expression in peripheral blood (PB) and brain to 
evaluate the usefulness of PB as a source of biomarkers that mirror the state of disease 
in the brain (6-8). Results from transcriptomic, proteomic and epigenomic analysis 
support the view that some genes, which expression is dysregulated in blood, might 
reflect specific changes that characterizes the abnormal biological processes in CNS (9-
12). Therefore, in recent years, there has been an intensive search for this type of 
biomarker as a useful and cheaper alternative for SZ (13).
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Here, we sought to identify gene expression markers in PB that may be useful as 
biomarkers of development and disease evolution in SZ. We first performed an 
expression microarray analysis in blood samples from male SZ patients with several 
years of illness duration for comparison to controls. To prioritize biomarkers, a systems 
biology approach was used based on weighted gene coexpression network analysis 
(WGCNA), and the discriminating performance of candidate genes was further tested 
in an independent cohort of patients with first-episode SZ.
2. Methods
2.1 Peripheral sample cohorts
Thirty unrelated male patients with SZ were recruited at the Psychiatric Out-patient 
Unit of the Clinic Hospital of Valencia University, Spain (cohort 1). The control group 
(CNT) consisted of 15 age-matched healthy males without a history of drug abuse or 
familial background of mental disorders. A second sample of 124 patients with first-
episode SZ (62 males) and 54 healthy controls (30 males) were recruited from the 
University Hospital Marqués de Valdecilla in Santander, Spain (cohort 2). Detailed 
description of these cohorts is shown in the supplementary material and 
supplementary Table 1. This study was performed according to the guidelines of each 
institution involved and was approved by the Local Ethics Committee of each 
participating center. 
2.2 Postmortem sample
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Frozen RNA from the postmortem frontal cortex and cingulate cortex was obtained 
from the Stanley Medical Research Institute Array Collection 
(http://www.stanleyresearch.org/brain-research/array-collection). Postmortem brain 
samples were from donor subjects with SZ (n = 35) and controls with no history of 
psychosis (n = 34). The distributions of age and gender in the two groups remained 
similar. The tissue characteristics of this sample are detailed in Supplementary Table 2.
2.3 Expression microarray analysis
PB of subjects from cohort 1 was collected in RNA-stabilizing PAXgene tubes (Qiagen, 
Izasa, Spain). Total RNA was extracted from the obtained cells using the PAXgene 
blood RNA Kit (Qiagen, Izasa, Spain) according to the manufacturer's protocol 
(supplementary Table 1). Gene expression analysis was performed using the GeneChip 
Human Gene 2.0 ST Array (Affymetrix, Santa Clara, CA, USA) covering more than 
750,000 unique 25-mer oligonucleotide features constituting over 40,000 RefSeq 
transcripts. Hybridization experiments and microarray data generation were 
conducted in the Central Unit for Research in Medicine Faculty-INCLIVA, University of 
Valencia (Spain). A gene expression profile was obtained for each subject in cohort 1.
2.4 Gene coexpression network analysis
WGCNA package in R(14) was used to calculate the coexpression network from the 
reduced gene set (24618 probes). We initially identified the value that transformed the 
data into an approximate scale-free topology. Next, we used Pearson’s correlation 
coefficient, a minimum module size of 30 genes and a minimum height value of 0.25 to 
merge modules (groups of highly correlated genes). For the functional annotation of 
the network modules associated with the different traits, we used the Database for 
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Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/home.jsp). We considered only those results with a false 
discovery rate of 0.05 to be significantly enriched. DAVID analysis results were 
visualized using the EnrichmentMap 2.0.1(15) plugin for Cytoscape 3.3.0 
(http://cytoscape.org). For detailed description see supplementary material. 
2.5 Reverse transcription quantitative PCR (RT-qPCR)
Total RNA of subjects from cohort 1 was converted into cDNA with Expand Reverse 
Transcriptase and hexanucleotide mix (Roche Applied Science, Indianapolis, USA), 
following the experimental conditions as previously described (16). 
Amplification was conducted with an ABI PRISM 7700 Sequence Detector (Applied 
Biosystems) as previously described(16), using 5X HOT FIREPol EvaGreen qPCR Mix Plus 
(Solis BioDyne, Estonia) and gene-specific primers (Supplementary Table 3). 
2.6 RNA sequencing (RNA-seq)
Total RNA was extracted from the PB of individuals from cohort 2. mRNA was isolated 
from the total RNA and was fragmented once transformed into cDNA. Fragments of 
300 bp on average were selected to construct the libraries for sequencing. Pair-end 
sequences of 70 nucleotides for each end were produced. Then it was sequenced using 
Illumina HiSeq instruments (San Diego, CA, USA).
RT-qPCR and RNA-seq analyses are further described in the supplementary material.
2.7 Statistical analyses 
Demographic, clinical and tissue features of cohorts were compared using ANOVA and 
t-test. Statistical significance was indicated at p < 0.05. To identify potential blood 
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biomarkers for SZ contributing to the differentiation between control individuals and 
patients, a binary logistic regression was carried out with the gene expression data. A 
significance test of the Wald statistic was conducted to investigate genes whose 
expression is significantly associated in the final equation (p < 0.05). All statistical 
analyses were performed using SPSS v14.0 software (SPSS, Chicago, IL).
3. Results
3.1 Gene expression array analysis
Whole transcriptome analysis in PB samples of cohort 1 was performed to identify 
potential biomarkers in SZ. We focused on male subjects to minimize sex differences in 
gene expression. We identified 10 modules of correlated genes (genes with similar 
expression attending to the different groups studied and variables of the sample), each 
one of them was coded with an arbitrary color, and an eleventh gray module 
containing the genes that were not part of any particular module. The functional 
annotation of each module is shown in Supplementary Table 4.
The main purpose of the analysis was to identify genes whose expression was 
associated with the clinical condition (CNT versus SZ). We specified a significance 
threshold of p-value ≤ 0.05 for the correlation between connected-gene modules and 
traits. According to this threshold, four modules (turquoise, purple, yellow and blue) 
significantly correlated with the clinical condition (Figure 1), which means that there 
are differences in gene expression levels among CNT versus SZ. In addition, two 
modules (magenta and blue) were correlated with the patient condition, which 
accounts for differences in gene expression levels between SZ patients with and 
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without auditory hallucinations. Three modules (turquoise, purple and yellow) were 
associated with medication (supplementary Table 5); two modules (black and pink) 
correlated with RNA purity and one module (black) with the subject’ age. Importantly, 
we did not identify any highly connected gene module specifically related to 
chlorpromazine dosage under the thresholds applied (Figure 1).
Figure 1:  Relationship between the different traits analyzed (RNA purity measured as 
A260/A280 and A260/230; Clinical condition; Patient condition; Age; Medication; 
Chlorpromazine equivalent) and gene modules using the WGCNA approach. Gene modules 
are designated by different colors on the left, color scheme on the right (blue-red) denotes 
the correlation (-1 to 1) between module and trait, and the p-value of the correlation in 
each interaction is indicated in brackets. 
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3.2 Selection of candidate genes as potential blood biomarkers in schizophrenia
We selected modules that were significantly correlated with the clinical or the patient 
conditions (with a cutoff value of p ≤ 0.02 at least in one of these conditions) but that 
showed no correlation with the other traits analyzed. Gene expression in the blue 
module (Figure 1) is associated with the clinical condition (p = 0.02) and patient 
condition (p = 0.03). Purple and turquoise modules showed correlations with the 
clinical condition (p = 0.02 and 0.01, respectively). In these two modules, medication 
might have an effect on the expression of the included genes (p = 0.03 and p = 0.01, 
respectively). No significant effect was observed for the remaining confounding 
factors. Finally, the magenta module is associated with the patient condition (p = 0.02).
Next, we chose genes from the selected modules (Supplementary Figures 1-4), whose 
expression differed in the clinical or patient condition traits with high statistical 
significance (p < 0.001 in the blue and turquoise modules because they included a high 
number of genes; p < 0.01 for purple and magenta modules, with fewer genes). A total 
of 14 genes were selected; CPQ, MSL1, NRD1, SRPK1, CMTM5, APOBEC3G, NKG7, 
SLAMF6, TOX, C12orf73, EIF2D, RNPS1, KPL29P2 and SIGIRR (supplementary Table 6). 
These genes are involved in different biochemical pathways, including proteolysis, 
chromatin organization and RNA splicing (turquoise module); chemotaxis (magenta 
module); cytidine deamination, inflammatory process, protein binding, regulation of 
immune response and DNA regulation (purple module); and gene expression, 
translation initiation, signal transduction and unknown functions (blue module). 
Expression of these genes was measured by RT-qPCR and compared between the 
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control group and the SZ patients in cohort 1 (Supplementary Figure 5). We found 
differences in two of them. The expression of the Eukaryotic Translation Initiation 
Factor 2D (EIF2D) gene was increased in SZ patients versus controls (fold change = 
2.05, p = 0.008, Figure 2A). On the contrary, the expression of the Thymocyte Selection-
Associated High Mobility Group Box (TOX) gene was reduced in the SZ group (fold 
change = 0.6, p = 0.017, Figure 2A). 
Figure 2. A) Boxplots representing the quartiles of the relative gene expression values for 
the EIF2D and TOX in cohort 1; controls (CNT) are compared with schizophrenia patients 
(SZ). * p<0.05. B) Boxplots in cohort 2, CNT are compared with the SZ patients at the onset 
of the disease (SZ 0), after 3 months (SZ 3 M) and 1 year of disease onset (SZ 1Y), *** 
p<0.001.
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Next, we studied the expression of both genes in prefrontal and cingulated post-
mortem brain regions, which have been largely associated with SZ symptoms, and no 
significant changes were observed (Supplementary Figure 6).
3.3 Predictive Model Equation 
Using binary logistic regression, we obtained a predictive equation in which EIF2D and 
TOX gene expression could differentiate the SZ patients versus controls in cohort 1. 
The final equation model is -0.106 + [2.957 × EIF2D] + [-4.198 × TOX], where EIF2D and 
TOX respectively indicate the expression levels of these genes. Applying this equation 
to subjects in cohort 1, SZ patients were distinguished from healthy controls with 
86.5% accuracy, with 0.5 as a cutoff value (Supplementary Table 7).
3.4 Gene expression biomarkers in a new cohort 
We assessed the predictive value of the 14 selected genes by measuring their 
expression in a new cohort (cohort 2). Gene expression was analyzed with RNA-seq 
data at disease onset (0), after 3 months (3M) and after 1 year (1Y) of disease onset. In 
this case, we also found significant differences in EIF2D expression between controls 
and patients, but EIF2D mRNA levels were lower in patients than controls, contrary to 
what we observed in cohort 1. This reduction was found at the 3 time points tested 
(fold change at disease onset = 0.88; after 3 months = 0.87; after 1 year = 0.87, p < 
0.0001 in all cases (Figure 2B). TOX expression was reduced in the SZ patients as in 
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cohort 1, although this change showed a trend at time point 0 and was not significant 
at 3M or 1Y (Figure 2B). 
Next, we investigated a new predictive model equation using the expression data of 
the 14 selected genes in the cohort 2. We again found that EIF2D is included in a 
predictive model at each of 3 time points, but not TOX (Supplementary Table 8). 
Nevertheless, the predictive values of EIF2D expression in cohort 2 were found to be in 
opposite directions relative to those in cohort 1.
3.5 EIF2D changes with disease duration
We found that EIF2D expression increased in SZ patients in cohort 1 but decreased in 
SZ patients in cohort 2 regarding to the corresponding controls. Cohort 1 includes men 
with chronic SZ, while cohort 2 is composed of first-episode patients of both sexes 
evaluated over 1 year from the disease onset (Supplementary Table 1). To examine the 
potential effect of sex on EIF2D expression, we compared EIF2D mRNA levels only in 
men from cohort 2. We found a result similar to that described before for all samples, 
including men and women. Next, we compared EIF2D expression with respect to 
disease duration in SZ patients in cohort 1 and observed a positive correlation trend 
between EIF2D mRNA levels and years of disease (p = 0.0794; r = 0.35) (Figure 3A). 
Then, we grouped the SZ patients into those with a disease duration of less (n = 17) 
and more (n = 9) than 10 years. When comparing the EIF2D expression between both 
subgroups of SZ patients, we found a trend of an increase in the expression levels of 
EIF2D (p = 0.0634) in patients suffering from the disease more than 10 years compared 
with the SZ patients from the other subgroup (Figure 3B).
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Figure 3: EIF2D expression with disease duration in SZ patients in cohort 1. A)  
Correlation between EIF2D mRNA level and the years of the disease in the SZ patients in 
cohort 1. B) Differences in EIF2D expression in SZ patients with less than 10 years of the 
disease compared with SZ patients with more than 10 years of the disease.
4. Discussion
The identification of PB biomarkers for SZ risk assessment has become a new and 
promising area of translational investigation in psychiatry. Our results revealed that 
the expression levels of EIF2D and TOX could discriminate between SZ patients and 
controls with 86.5% accuracy in the cohort 1.
EIF2D encodes a factor involved in a noncanonical translation initiation mechanism of 
protein synthesis that is believed to operate mainly in cells under stress (17). The 
A
B
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expression of the yeast orthologue gene rises under some stresses, such as anoxia, 
oxidative stress and accumulation of unfolded proteins in the endoplasmic reticulum. 
In these situations, the activity of eIF2, which participates in the canonical eukaryotic 
translation initiation pathway, is suppressed (17). In mammalian cells, eIF2 function is 
also blocked by different stress conditions (18). Our results of a two-fold increase in 
EIF2D mRNA levels in SZ patients relative to the levels in controls suggest the presence 
of cellular stressors in SZ patients. A growing body of data supports the implication of 
oxidative and endoplasmic reticulum stress in SZ (reviewed in(19)). Most studies 
analyzing markers of oxidative status, such as glutathione, in blood and in neural 
tissues point out oxidative imbalance in this disease (20, 21).
On the other hand, EIF2D has been involved in translation control of cellular mRNAs 
having short regulatory upstream open reading frames in the 5’UTR (22, 23). A large 
number of mammalian proteins are regulated by this mechanism, including many 
proteins needed for cell growth and proliferation (22). Other noncanonical initiation 
factors, DENR (density regulated protein) and MCT-1 (product of malignant T cell-
amplified sequence 1 oncogene), also promote the translation reinitiation process 
through the DENR-MCTS1 complex (22, 23). Interestingly, missense mutations in DENR 
have been reported in unrelated patients with autism spectrum disorder (24). These 
results highlight the importance of proper mRNA translation reinitiation processes for 
brain development. We can speculate that higher EIF2D doses above its physiological 
level could also interfere with the translation reinitiation mechanism. In this line, 
increasing the levels of eIF4E in mice resulted in exaggerated cap-dependent 
translation and autistic-like behaviors (25). Finally, EIF2D is located on 1q32.1, a 
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chromosomal locus in which several studies have reported genetic linkage with SZ(26, 
27).
TOX is an evolutionarily conserved member of the HMG-box family of transcription 
factors that has been studied mainly in the immune system and hematopoiesis (28, 
29). TOX is necessary for the development of some cells of the adaptive and innate 
immune systems including CD4+ T cells, natural killer cells and lymphoid tissue inducer 
cells (30, 31). Interestingly, a high number of studies related dysregulation of immune 
and inflammatory function with SZ (13, 32). Remarkably, inflammation is closely 
interconnected with oxidative stress, being both a cause and a consequence, and vice 
versa (33). In addition, Tox expression in the mouse thymus is calcineurin dependent 
(34), and the calcineurin pathway has been proposed to be implicated in the 
pathogenesis of SZ (35). In neural tissues, Tox functions as an important regulator of 
neural stem cell proliferation and dendritogenesis, and its expression in the brain is 
also controlled by calcineurin (36). However, the changes in expression of EIF2D and 
TOX that we found in PB were not observed in the prefrontal and cingulated regions 
analyzed when comparing SZ patients with controls (Supplementary Figure 6), but 
these genes might be dysregulated in specific cell types and/or other different brain 
areas. In line, regionally specific changes in gene expression in SZ have been found in 
postmortem brain tissue samples (37).
To further assess the predictive value of the 14 selected genes for SZ risks, we analyzed 
their expression in a second independent cohort of patients and controls. This sample 
comprised first-episode SZ patients and then, its comparison with the chronic SZ 
subjects from cohort 1 could also reveal potential PB biomarkers dependent on the 
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disease evolution. In cohort 2, TOX expression was also reduced with respect to 
controls, but it was not significant. In this cohort, we also found significantly altered 
expression of EIF2D between the first-episode SZ patients and control subjects; 
however, EIF2D mRNA levels were reduced in this case. This finding contrasts with the 
increased EIF2D mRNA levels in the chronic patients of cohort 1. The reduction of 
EIF2D expression in patients of cohort 2 was similar in the three time points tested 
during the first year of disease duration, suggesting that medication probably did not 
affect EIF2D expression. The different results obtained for this gene in the SZ patients 
of the cohorts 1 and 2 might be explained by the disease state. In line with these 
findings, we observed a trend toward increased EIF2D expression in patients suffering 
from the disease for more than 10 years compared with patients with less than 10 
years of illness. Therefore, the expression level of this gene may be indicative of redox 
status in PB revealing higher redox dysregulation after several years of disease 
progression. This result agrees with lower antioxidant response found in SZ patients 
with longer duration of illness (38).  So, EIF2D expression may show a stage of disease 
progression. Future longitudinal studies in the first-episode SZ patients are needed to 
address this question together with molecular approaches to identify the underlying 
mechanism.
One of the limitations of our work is the sample size, but it is comparable to that used 
in other studies looking for biomarkers in human tissues (39, 40). Then further analysis 
should be followed up in larger cohorts at different time points and in different 
postmortem brain regions to compare the results. In addition, we cannot exclude the 
possibility that medication may have an effect on gene expression levels. It could be, in 
part, the cause of the differences found between the two cohorts, since the cohort 1 is 
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composed by long term medicated chronic patients and the cohort 2 is composed by 
naïve patients. Nevertheless, the significant reduction of EIF2D expression in cohort 2 
was maintained during the first year of the disease, when the patients are already 
medicated. Moreover, we tried to reduce the effect of this variable in the first 
discrimination point, excluding the nodes of genes associated with medication. Finally, 
different approaches have been used to study gene expression (RNA microarray, RT-
qPCR and RNA sequencing), which could result in some variability in the final results. 
Nevertheless, all the techniques are evaluating the differences in gene expression. 
Also, appropriate controls were chosen to discard any alteration of the techniques and 
all methods have been normalized to minimize such technical deviations. In 
conclusion, we can underline the potential implication of protein synthesis regulation, 
oxidative stress and immune processes in the development and prognosis of SZ, 
marked by the expression of EIF2D and TOX genes in our samples. Our results support 
the use of antioxidants in SZ as an adjunctive treatment to standard antipsychotic 
medication.
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Highlights
- The EIF2D and TOX genes, involved in protein synthesis and immune function 
are blood markers of schizophrenia. 
- EIF2D gene expression in blood changes with disease duration.
- EIF2D as a potential marker of schizophrenia disease status.
